The current study identifies mechanosensitive MDM4 as a novel molecular target in pulmonary fibrosis and highlights the therapeutic potential of targeting nonenzymatic AGE cross-linking to reverse persistent lung fibrosis associated with aging. This evidence concerns the gene MDM4 and pulmonary fibrosis.